CorMedix Inc. to Host Regulatory Update Conference Call
March 08 2021 - 5:00PM
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused
on developing and commercializing therapeutic products for the
prevention and treatment of infectious and inflammatory disease,
today announced that it will host a conference call relating to a
regulatory update for DefenCath™ at 8:30am ET on March 9, 2021.
Tuesday, March 9th @
8:30am ET |
Domestic: |
877-423-9813 |
International: |
201-689-8573 |
Conference
ID: |
13717520 |
Webcast: |
Webcast
Link |
About CorMedixCorMedix Inc. is
a biopharmaceutical company focused on developing and
commercializing therapeutic products for the prevention and
treatment of infectious and inflammatory diseases. The Company is
focused on developing its lead product DefenCath™, a novel,
antibacterial and antifungal solution designed to prevent costly
and life-threatening bloodstream infections associated with the use
of central venous catheters in patients undergoing chronic
hemodialysis. DefenCath has been designated by FDA as Fast Track
and as a Qualified Infectious Disease Product, which provides an
additional five years of marketing exclusivity, which will be added
to the five years granted to a New Chemical Entity upon approval of
the NDA. CorMedix also intends to develop DefenCath as a catheter
lock solution for use in oncology and total parenteral nutrition
patients. It is leveraging its taurolidine technology to develop a
pipeline of antimicrobial medical devices, with programs in
surgical sutures and meshes, and topical hydrogels. The
Company is also working with top-tier researchers to develop
taurolidine-based therapies for rare pediatric cancers.
Neutrolin® is CE Marked and marketed in Europe and other
territories as a medical device. For more information,
visit: www.cormedix.com.
Investor Contact:Dan FerryManaging
DirectorLifeSci Advisors(617) 430-7576
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024